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Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416 A361Conclusions: A single IA administration of 40 mg of FX006 maintained
pharmacologically active synovial ﬂuid concentrations of TCA for at
least 12 weeks, while TCA IR produced levels that are below the lower
limit of quantitation by 6weeks. These data underpin the differentiation
of FX006 from TCA IR and provide pharmacokinetic basis for previously
demonstrated prolongation and ampliﬁcation of pain relief compared to
TCA IR in OA patients following a single IA injection. FX006 also has the
potential for an improved systemic safety proﬁle as evidenced by peak
plasma concentrations that are 40-fold lower than TCA IR at the same
dose, seen in the aggregate of clinical studies with FX006 to date.
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GASTROINTESTINAL SAFETY AND TOLERABILITY OF LONG-TERM
GCSB-5 OF DRIED EXTRACTS OF SIX HERBS IN PATIENTS WITH
OSTEOARTHRITIS: A 24 WEEKS, MULTI-CENTERS, SINGLE ARM
PHASE IV STUDY
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Purpose: A previous study on GCSB-5 was shown to be non-inferior to
Celecoxib in efﬁcacy and safety in treating osteoarthritis, but its safety
information on the gastrointestinal (GI) safety is limited to only 12weeks.
A longer term (24 weeks) study with a larger number of patients is nec-
essary to establish the GI safety of GCSB-5. The primary goal of this study
was to determine the incidence of GI disorders associated with GCSB-5.
The secondary goal was to collect 24-week safety data of GCSB-5.
Methods: A single arm safety study on 24-week GCSB-5 was conducted.
Additionally, the results of this study were compared with Historical
Data of Celecoxib. This study was performed in 19 academic institutions
between May 2012 and June 2013. Two GCSB-5 capsules (300 mg per
capsule) were prescribed two times per day for 24weeks. Incidence of GI
disorders was the primary outcome. Incidence of GI perforation, ulcer
obstruction and bleeding (PUB), gastroduodenal ulcer, and dropout due
to GI complications were the major secondary outcome variables.
Results: A total of 761 patients with osteoarthritis were enrolled and
756 patients took at least one dose of study drug. A total of 629 patients
(82.7%) completed the 24 weeks follow-up visit. The incidence of GI
disorders among the 756 patients with or without aspirin exposure was
23.7%. Aspirin use did not show any signiﬁcant difference in GI dis-
orders. The annualized incidence rate of PUB was 0.0%. The annualized
incidence rate of gastroduodenal ulcer was 0.0%. The drop-out rate due
to GI disorders in GCSB-5 was 4.8%. As the results compared with His-
torical Data of Celecoxib, the incidence of GI disorders (29.9%),
annualized rate of PUB and gastroduodenal ulcer (2.2%), and drop-out
rate (8.7%) due to GI disorders for Celecoxib were signiﬁcantly higher
than GCSB-5.
Conclusions: This study indicated GCSB-5 was safe for patients with
osteoarthritis during long-term treatment. Furthermore, the safety
results of GCSB-5 associated with GI disorder were comparable to
Celecoxib.
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THE EFFECT OF PREOPERATIVE PAIN TREATMENT BY MEANS OF
DULOXETINE ON POSTOPERATIVE OUTCOME AFTER TOTAL HIP OR
KNEE ARTHROPLASTY: DESIGN OF A PRAGMATIC RANDOMIZED
CONTROLLED TRIAL
T. Blikman y, W. Rienstra y, T.M. van Raaij z, S.K. Bulstra y, M. Stevens y,
I. van den Akker-Scheek y. yUniv. Med. Ctr. Groningen, Groningen,
Netherlands; zMartini Hosp. Groningen, Groningen, NetherlandsPurpose: Total joint replacement (TJR) is considered to be one of the
most safe, successful, and cost-effective treatments for advanced
osteoarthritis (OA). However, residual pain seems to be a major factor of
patient’s dissatisfaction following Total Hip Arthroplasty/Total Knee
Arthroplasty (THA/TKA). The proportion of patients suffering from
unfavourable long-term residual pain is relatively high, proportions
ranging from 10 to 34% after knee and 7 to 23% after hip replacement
surgery. Changes within the central nervous system are presumably
accountable for accessory pain ampliﬁcation and sensitization. Cur-
rently there are studies indicating that a preoperative degree of central
sensitisation (CS) is associated with poorer postoperative outcomes and
residual pain. Thus, it could be hypothesized that preoperative treat-
ment of CS could enhance postoperative outcomes. Duloxetine, a
combined serotonin and norepinephrine reuptake inhibitor (SNRI), has
shown to be effective in several chronic pain syndromes, including
knee-OA, in which CS is likely one of the underlying pain mechanisms.
This study aims to evaluate the postoperative effects of preoperative
screening and targeted duloxetine treatment of CS on residual pain,
compared to care as usual.
Methods: This multi-centre, pragmatic, prospective, open-label,
randomized controlled trial (RCT) includes adults which are on the
waiting list for primary THA/TKA, with a possible or likely neuropathic
pain (NP) phenotype at screening (deﬁned by a score >12 point on the
modiﬁed-painDETECT questionnaire), hence this will probably identify
patients who are more likely to experience CS. Patients will be ran-
domly allocated to the preoperative “duloxetine treatment group” (1
week initiation 30 mg/d, 7 weeks 60 mg/d, 2 weeks taper-phase 30 mg/
d) or the “care as usual group” (no speciﬁc preoperative intervention).
The primary endpoint is the degree of postoperative pain 6 months
after THA/TKA, assessed with the pain subscale of the Hip disability/
Knee injury and Osteoarthritis Outcome Score (HOOS/KOOS). Secondary
endpoints, at multiple pre- and postoperative time points (up to 12
months postoperative) will be; pain, neuropathic pain (NP), sensitisa-
tion (pressure pain thresholds, temporal summation), quality of life and
depressive/anxiety symptoms. Furthermore, factors such as perceived
satisfaction and arthroplasty related expectations will be analyzed.
Based on a minimally clinical important difference of 10 points on the
HOOS/KOOS; a total of 118 patients are anticipated to be randomized to
detect a clinical relevant difference (80% power, 20% protocol violators
and/or dropout included).
Results: Data analysis will be conducted on an intention-to-treat basis.
In case of the primary endpoint a Student’s t-test (or a non-parametric
equivalent in case of a skewed distribution) will be used to determine if
there is a difference in pain on the HOOS/KOOS at 6 months post-
operative between the two groups. GEE (Generalized Estimating
Equation) analysis will be used to determine whether there is a differ-
ence on pain between the two groups over time, adjusted for relevant
covariates. The same principles will be used to asses the secondary time
points. A P-value of < 0.05 is considered statistically signiﬁcant.
Conclusions: This study is, as far as we know, the ﬁrst pragmatic RCT
assessing the postoperative effects of a preoperative targeted dulox-
etine treatment in OA-patients suffering from a degree of preoperative
CS (indicated by a possible or likely NP-phenotype). We believe a
pragmatic trial design is valid; hence it mimics the “real life status”,
with a “care as usual” control group, as much as possible. Furthermore,
the endpoints are, unlike placebo controlled explanatory trials, more
focused on the relevancy to everyday life; like hip and knee speciﬁc
pain, function and quality of life. Knowledge gained with this study can
potentially improve postoperative pain relief and rehabilitation after
TJR.
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DIFFERENTIAL PROFILING OF SECRETOMES FROM HUMAN
CARTILAGE TO IDENTIFY POTENTIAL EARLY SPECIFIC PROTEIN
BIOMARKERS IN OSTEOARTHRITIS
L. Lourido, V. Calamia, P. Fernandez-Puente, J. Mateos, B. Rocha,
C. Fernandez-Costa, C. Fernandez-Lopez, N. Oreiro, F.J. Blanco,
C. Ruiz-Romero. INIBIC e CHU A Coru~na, A Coru~na, Spain
Purpose: Osteoarthritis (OA) is characterized by the progressive loss of
cartilage structural extracellular matrix (ECM) components. The release
of these proteins from the tissue can vary according to the stage of the
disease and the speciﬁc joint affected. The aim of this study was to
